[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620878":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":38,"id":60,"slug":38,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":38,"enrollmentInfo":69,"targetDuration":38,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":38,"overallStatus":43,"whyStopped":38,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nifedipine and Enalapril","EXPERIMENTAL","Nifedipine 60mg by mouth every twelve hours plus Enalapril 5mg by mouth every twelve hours",[13],"Drug: Nifedipine and Enalapril",{"label":15,"type":16,"description":17,"interventionNames":18},"Nifedipine and Labetalol","ACTIVE_COMPARATOR","Nifedipine 60mg by mouth every twelve hours plus Labetalol 200mg by mouth every twelve hours",[19],"Drug: Nifedipine and Labetalol",[21,26],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],[25],"Procardia and Vasotec",{"type":22,"name":15,"description":17,"armGroupLabels":27,"otherNames":28},[15],[29],"Procardia and Trandete",[31],{"name":32,"affiliation":5,"role":33},"Amol Malshe, M.D.","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","216 903-9646",null,"malshea@ccf.org",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Cleveland Clinic","RECRUITING","Cleveland","Ohio","44195","United States",{"type":49,"coordinates":50},"Point",[51,52],-81.69541,41.4995,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":57,"phoneExt":38,"email":39},"Amol Malshe","216-903-9646",{"type":59,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100620878",false,"NCT07363343","Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study","Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NEPHRON)","NEPHRON","Inclusion Criteria:\n\n* Postpartum women aged 18 years or older\n* Clinical diagnosis of hypertensive disorder in pregnancy (gestational hypertension, chronic hypertension, preeclampsia with or without severe features)\n* Taking Nifedipine 60 mg every 12 hours for blood pressure control\n* Persistently elevated blood pressure at\u002Fabove 140\u002F90 mmHg in a 24-hour time period or have one or more severe range blood pressure at\u002Fabove 160\u002F110 mmHg requiring a second antihypertensive medication\n* English speaking\n\nExclusion Criteria:\n\n* Taking ≥2 antihypertensive agents during pregnancy\n* Heart block\n* Heart rate \\\u003C60 or \\>120 beats per minute\n* Heart failure\n* Creatinine \\>1.5 mg\u002FdL\n* Renal artery stenosis\n* Active connective tissue disease\n* Cerebrovascular accident\n* Failed treatment or contraindications to nifedipine, enalapril or labetalol","FEMALE","18 Years",{"count":70,"type":71},200,"ESTIMATED","INTERVENTIONAL",[74],"NA","To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.",[77,78],"Hypertension","Postpartum Preeclampsia","2026-06-11",{"date":81,"type":82},"2026-06-12","ACTUAL",{"date":84,"type":82},"2026-03-10",{"date":86,"type":71},"2029-12-31",{"name":5,"class":6},1]